Claims for Patent: 6,051,402

Summary for Patent: 6,051,402

Title:	Compositions and methods for treating sickle cell disease
Abstract:	Gene therapy methods and compositions for high level expression of anti-sickling globin proteins in erythroid cells for treating Sickle Cell disease are described.
Inventor(s):	LeBoulch; Philippe (Cambridge, MA), London; Irving M. (Cambridge, MA)
Assignee:	Massachusetts Institute of Technology (Cambridge, MA)
Application Number:	09/234,009
Patent Claims:	1. An isolated nucleic acid molecule encoding an anti-sickling .beta.-globin protein having structure of human .beta.-globin and comprising the amino acid sequence shown in SEQ ID NO:1, wherein at least one amino acid residue of SEQ ID NO:1 has been substituted with an anti-sickling amino acid residue selected from the group consisting of: 9 Thr, 12 Asn, 22 Ala, 50 Ser, 80 Asp, 86 Ser, 87 Gln, 116 Arg, 117 Asn, 125 Gln and 126 Met, provided that said anti-sickling .beta.-globin protein does not contain all of said anti-sickling residues, wherein said anti-sickling .beta.-globin protein exhibits reduced sickling compared to wild-type .beta.-globin protein when present in a hemoglobin tetramer along with at least one .beta.6 Val mutated .beta.-globin protein. 2. The nucleic acid molecule of claim 1, wherein said anti-sickling amino acid residue is selected from the group consisting of: 9 Thr, 12 Asn, 22 Ala, 50 Ser, 86 Ser, 87 Gln, 116 Arg, 117 Asn, 125 Gin, and 126 Met. 3. The nucleic acid molecule of claim 1, wherein the anti-sickling .beta.-globin protein has the amino acid sequence shown in SEQ ID NO:2. 4. The nucleic acid molecule of claim 1, wherein said molecule is DNA. 5. The nucleic acid molecule of claim 1, wherein said molecule is RNA. 6. An isolated DNA construct comprising the DNA molecule of claim 4 and a promoter recognized by a DNA polymerase. 7. The DNA construct of claim 6, wherein the DNA polymerase is erythroid specific. 8. The DNA construct of claim 7, wherein the promoter is selected from the group consisting of the .beta.-globin promoter and the HPFH promoter. 9. The DNA construct of claim 6, said DNA construct further comprising an enhancer. 10. The DNA construct of claim 9, wherein the enhancer is the DNAse I hypersensitive site 2 of the human .beta. Locus Control Region and/or the second intron of the .beta.-globin gene. 11. The DNA construct of claim 9, additionally comprising DNA encoding a selectable marker under the control of the same or an additional promoter. 12. An isolated RNA construct comprising the RNA molecule of claim 5 and a promoter recognized by a RNA polymerase. 13. The RNA construct of claim 12, wherein the RNA polymerase is erythroid specific. 14. The RNA construct of claim 12, said DNA construct further comprising an enhancer. 15. The RNA construct of claim 14, additionally comprising RNA encoding a selectable marker under the control of the same or an additional promoter. 16. A vector comprising the DNA construct of claim 7, said expression vector further comprising elements for infecting and stably maintaining said DNA molecule in erythroid cells. 17. The vector of claim 16, wherein the elements are selected from the group consisting of: retrovirus, adenovirus, adeno-associated virus and naked plasmid. 18. The vector of claim 17, wherein the elements are retrovirus elements. 19. Erythroid cells comprising the vector of claim 16. 20. The erythroid cells of claim 19, wherein said erythroid cell is selected from the group consisting of: stem cells, burst forming unit cells, colony forming unit cells, nucleated red blood cells and mature red blood cells.

Details for Patent 6,051,402

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2014-09-19
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2014-09-19
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2014-09-19